These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 11003633)

  • 1. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.
    Hadziyannis SJ; Papatheodoridis GV; Dimou E; Laras A; Papaioannou C
    Hepatology; 2000 Oct; 32(4 Pt 1):847-51. PubMed ID: 11003633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease.
    Papatheodoridis GV; Dimou E; Laras A; Papadimitropoulos V; Hadziyannis SJ
    Hepatology; 2002 Jul; 36(1):219-26. PubMed ID: 12085368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term therapy of chronic hepatitis B with lamivudine.
    Lau DT; Khokhar MF; Doo E; Ghany MG; Herion D; Park Y; Kleiner DE; Schmid P; Condreay LD; Gauthier J; Kuhns MC; Liang TJ; Hoofnagle JH
    Hepatology; 2000 Oct; 32(4 Pt 1):828-34. PubMed ID: 11003630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy.
    Dienstag JL; Schiff ER; Mitchell M; Casey DE; Gitlin N; Lissoos T; Gelb LD; Condreay L; Crowther L; Rubin M; Brown N
    Hepatology; 1999 Oct; 30(4):1082-7. PubMed ID: 10498663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Durability of serologic response after lamivudine treatment of chronic hepatitis B.
    Dienstag JL; Cianciara J; Karayalcin S; Kowdley KV; Willems B; Plisek S; Woessner M; Gardner S; Schiff E
    Hepatology; 2003 Apr; 37(4):748-55. PubMed ID: 12668966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy.
    Kazim SN; Chauhan R; Das BC; Sarin SK
    J Gastroenterol Hepatol; 2006 Oct; 21(10):1525-32. PubMed ID: 16928212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in serum hepatitis B e antigen (HBeAg) levels associated with the emergence of YMDD mutants in HBeAg non-seroconverted patients during lamivudine therapy.
    Yen YH; Lu SN; Chen CH; Wang JH; Wu CM; Hung CH; Tseng PL; Hu TH; Changchien CS; Lee CM
    Liver Int; 2007 Dec; 27(10):1349-55. PubMed ID: 18036099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.
    Leung NW; Lai CL; Chang TT; Guan R; Lee CM; Ng KY; Lim SG; Wu PC; Dent JC; Edmundson S; Condreay LD; Chien RN;
    Hepatology; 2001 Jun; 33(6):1527-32. PubMed ID: 11391543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lamivudine monotherapy in HBeAg-negative chronic hepatitis B: prediction of response-breakthrough and long-term clinical outcome.
    Manolakopoulos S; Bethanis S; Elefsiniotis J; Karatapanis S; Triantos C; Sourvinos G; Touloumi G; Economou M; Vlachogiannakos J; Spandidos D; Avgerinos A; Tzourmakliotis D
    Aliment Pharmacol Ther; 2006 Mar; 23(6):787-95. PubMed ID: 16556181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An extended two-year trial of lamivudine in Chinese patients with chronic hepatitis B.
    Yao G; Cui Z; Wang B; Yao J; Zeng M
    Chin Med J (Engl); 2002 Dec; 115(12):1814-8. PubMed ID: 12622930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China.
    Yao GB; Zhu M; Cui ZY; Wang BE; Yao JL; Zeng MD
    J Dig Dis; 2009 May; 10(2):131-7. PubMed ID: 19426396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A higher alanine aminotransferase level correlates with earlier hepatitis B e antigen seroconversion in lamivudine-treated chronic hepatitis B patients.
    Tseng TC; Liu CJ; Wang CC; Chen PJ; Lai MY; Kao JH; Chen DS
    Liver Int; 2008 Aug; 28(7):1034-41. PubMed ID: 18492018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: an 8-year follow-up study.
    Akuta N; Suzuki F; Suzuki Y; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
    J Med Virol; 2005 Apr; 75(4):491-8. PubMed ID: 15714490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.
    Wong VW; Wong GL; Tsang SW; Hui AY; Chim AM; Yiu KK; Chan HY; Chan FK; Sung JJ; Chan HL
    Antivir Ther; 2008; 13(4):571-9. PubMed ID: 18672536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy.
    Lok AS; Hussain M; Cursano C; Margotti M; Gramenzi A; Grazi GL; Jovine E; Benardi M; Andreone P
    Hepatology; 2000 Nov; 32(5):1145-53. PubMed ID: 11050068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of a quantitative HBV-DNA PCR assay in lamivudine treated hepatitis B-infected patients].
    Deal C; Ajana F; Canva V; Mouton Y; Yazdanpanah Y; Wattré P; Bocket L
    Ann Biol Clin (Paris); 2002; 60(5):581-8. PubMed ID: 12368144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels.
    Tseng TC; Liu CJ; Wang CC; Chen PJ; Lai MY; Chen DS; Kao JH
    Antivir Ther; 2009; 14(2):203-10. PubMed ID: 19430095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial.
    Chan HL; Wang H; Niu J; Chim AM; Sung JJ
    Antivir Ther; 2007; 12(3):345-53. PubMed ID: 17591024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of long-term lamivudine in chronic hepatitis B virus-infected children.
    Ozgenç F; Arikan C; Sertoz RY; Nart D; Aydogdu S; Yagci RV
    Antivir Ther; 2004 Oct; 9(5):729-32. PubMed ID: 15535410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lamivudine treatment in HBeAg-negative chronic hepatitis B patients with low level viraemia.
    Bozkaya H; Yurdaydin C; Idilman R; Tüzün A; Cinar K; Erkan O; Bozdayi AM; Erden E; Uzun Y; Cetinkaya H; Uzunalimoglu O
    Antivir Ther; 2005; 10(2):319-25. PubMed ID: 15865226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.